Novartis http://www.globalpost.com/taxonomy/term/27889/all en Reuters Health News Summary http://www.globalpost.com/dispatch/news/thomson-reuters/130125/reuters-health-news-summary-0 <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>Following is a summary of current health news briefs.</p> <p>Davos divided on tackling the scourge of obesity</p> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130125/reuters-health-news-summary-0" target="_blank">read more</a></p> Financial data vendors Health Labor Medicine Novartis Religion Social Issues Technology Thomson Reuters Fri, 25 Jan 2013 13:16:14 +0000 5739336 at http://www.globalpost.com Novartis head gives up pay-off after storm of protest http://www.globalpost.com/dispatch/news/afp/130219/novartis-head-gives-pay-after-storm-protest <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>The outgoing head of Swiss pharmaceuticals giant Novartis, Daniel Vasella, has agreed to give up a massive pay-off, he said on Tuesday, after a nationwide storm of protest.</p> <p>"I have understood that many people in Switzerland find the amount of the compensation linked to the non-compete agreement unreasonably high, despite the fact I had announced my intention to make the net amount available for philanthropic activities," Vasella said in a statement released by Novartis.</p> <p><a href="http://www.globalpost.com/dispatch/news/afp/130219/novartis-head-gives-pay-after-storm-protest" target="_blank">read more</a></p> Business Daniel Vasella Daniel Vasella Novartis Novartis Pharmaceutical industry AFP Tue, 19 Feb 2013 09:30:31 +0000 5759691 at http://www.globalpost.com Novartis loses landmark India cancer drug patent case http://www.globalpost.com/dispatch/news/thomson-reuters/130401/indias-top-court-dismisses-novartis-petition-glivec-patent <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>By Kaustubh Kulkarni and Suchitra Mohanty</p> <p>MUMBAI/NEW DELHI (Reuters) - India's top court dismissed Swiss drug maker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for local makers of cheap generics.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130401/indias-top-court-dismisses-novartis-petition-glivec-patent" target="_blank">read more</a></p> BSE Sensex Business Cipla Health Hospitality Imatinib Indian Patent Office Labor Law Novartis Patent law Patent offices Pharmaceutical industry Pharmaceutical sciences Politics Social Issues Technology Thomson Reuters Mon, 01 Apr 2013 06:00:03 +0000 5798404 at http://www.globalpost.com URGENT ¥¥¥ Novartis loses Indian patent fight in landmark ruling http://www.globalpost.com/dispatch/news/afp/130401/urgent-novartis-loses-indian-patent-fight-landmark-ruling <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>India's top court denied Monday a patent request by Swiss drug giant Novartis for its cancer drug Glivec in a landmark decision seen as crucial for India's status as a global source of cheap medicines.</p> <p>The Supreme Court ruled that the compound for which Novartis was seeking a patent "did not satisfy the test of novelty or inventiveness" required by Indian law.</p> <p>str-pmc/adp/pj</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> Business Hospitality Imatinib Indian Patent Office Law Novartis Novartis Politics AFP Mon, 01 Apr 2013 06:00:16 +0000 5798405 at http://www.globalpost.com Novartis loses Indian patent fight in landmark ruling http://www.globalpost.com/dispatch/news/afp/130401/novartis-loses-indian-patent-fight-landmark-ruling <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>India's top court denied Monday a patent request by Swiss drug giant Novartis in a landmark ruling that activists say will protect access to cheap generic versions of drugs in developing nations.</p> <p>The Supreme Court ruled that the compound for a new version of its blockbuster cancer drug Glivec, for which Novartis was seeking a patent, "did not satisfy the test of novelty or inventiveness" required by Indian law.</p> <p>The judgement capped a seven-year legal battle by Novartis to win protection for the drug that went to the heart of India's patent law.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130401/novartis-loses-indian-patent-fight-landmark-ruling" target="_blank">read more</a></p> Business Hospitality Imatinib Indian Patent Office Law Novartis Politics AFP Mon, 01 Apr 2013 06:16:18 +0000 5798409 at http://www.globalpost.com URGENT ¥¥¥ Novartis condemns India patent ruling http://www.globalpost.com/dispatch/news/afp/130401/urgent-novartis-condemns-india-patent-ruling <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Swiss drugs giant Novartis condemned on Monday the Indian Supreme Court's dismissal of its patent bid for a blockbuster cancer drug, saying it "discourages future innovation".</p> <p>Novartis said in a statement the decision, which capped a seven-year legal battle to gain patent protection for an updated version of leukemia drug Glivec, "discourages innovative drug discovery essential to advancing medical science for patients".</p> <p>pmc/rob/jms</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> Business Hospitality Imatinib Law Novartis Novartis Politics AFP Mon, 01 Apr 2013 07:30:03 +0000 5798442 at http://www.globalpost.com Novartis India will continue to file for patents - executive http://www.globalpost.com/dispatch/news/thomson-reuters/130401/novartis-india-will-continue-file-patents-executive <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>MUMBAI (Reuters) - Novartis India Ltd, a unit of Swiss drugmaker Novartis AG, will continue to file for patents in India, its vice chairman said on Monday, after the country's top court rejected its plea for patent protection of its drug Glivec.</p> <p>Novartis India will also continue to invest there, but with caution, Ranjit Shahani, who is also the managing director of the company, told reporters after the Supreme Court judgment.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130401/novartis-india-will-continue-file-patents-executive" target="_blank">read more</a></p> Business Hospitality Imatinib Intellectual property law Law Novartis Politics Thomson Reuters Mon, 01 Apr 2013 10:00:03 +0000 5798488 at http://www.globalpost.com India hails "historic" Supreme Court drug patent ruling against Novartis http://www.globalpost.com/dispatch/news/thomson-reuters/130401/india-hails-historic-supreme-court-drug-patent-ruling-against-n <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>NEW DELHI (Reuters) - The Indian government hailed as "historic" a Supreme Court ruling on Monday against a plea by Swiss drugmaker Novartis AG to protect the patent on its drug Glivec.</p> <p>Commerce and Industry Minister Anand Sharma said the ruling -- seen as a victory by health rights campaigners -- reaffirmed provisions in Indian law that mandate the need for substantial innovation before new patents are issued on medicines.</p> <p>(Reporting By Matthias Williams; Writing by Frank Jack Daniel, editing by Ross Colvin)</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> Business Hospitality Imatinib Law Novartis Politics Thomson Reuters Mon, 01 Apr 2013 11:30:05 +0000 5798519 at http://www.globalpost.com Indian high court rules against drug company in patent fight http://www.globalpost.com/dispatch/news/agencia-efe/130401/indian-high-court-rules-against-drug-company-patent-fight <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agencia EFE </div> </div> </div> <!--paging_filter--><p>New Delhi, Apr 1 (EFE).- Swiss-based pharmaceutical giant Novartis AG saw its bid to patent a new version of a cancer medication blocked on Monday by the Indian Supreme Court.</p> <p>The judges agreed with activists and generic drug makers that the changes to cancer drug Glivec were not of sufficient magnitude to justify treating it as a new medication.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.efe.com" class="button wire efe"></a></p> <p><a href="http://www.globalpost.com/terms-use#efe"><span>Copyright EFE, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/agencia-efe/130401/indian-high-court-rules-against-drug-company-patent-fight" target="_blank">read more</a></p> Business Hospitality Law Novartis Pharmaceutical sciences Pharmaceuticals policy Politics Agencia EFE Mon, 01 Apr 2013 22:30:50 +0000 5798864 at http://www.globalpost.com Novartis loses landmark India patent case on Glivec http://www.globalpost.com/dispatch/news/asianet/130403/novartis-loses-landmark-india-patent-case-glivec <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Asianet </div> </div> </div> <!--paging_filter--><p></p><P> India's top court dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for local makers of cheap generics.</p><P>The decision sets a benchmark for intellectual property cases in India, where many patented drugs are unaffordable for most of its 1.2 billion people, and does not bode well for foreign firms engaged in ongoing disputes in India, including Pfizer Inc and Roche Holding AG, analysts said.</p> <p><a href="http://www.globalpost.com/dispatch/news/asianet/130403/novartis-loses-landmark-india-patent-case-glivec" target="_blank">read more</a></p> BSE Sensex Business Health Hospitality Imatinib Labor Law Novartis Politics Social Issues Technology Asianet Wed, 03 Apr 2013 15:50:15 +0000 Asianet 5800483 at http://www.globalpost.com Novartis loses landmark India cancer drug patent case http://www.globalpost.com/dispatch/news/asianet/130403/novartis-loses-landmark-india-cancer-drug-patent-case <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Asianet </div> </div> </div> <!--paging_filter--><p></p><P> India's top court dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for local makers of cheap generics, APA reports quoting Reuters.</p><P>The decision sets a benchmark for intellectual property cases in India, where many patented drugs are unaffordable for most of its 1.2 billion people, and does not bode well for foreign firms engaged in ongoing disputes in India, including Pfizer Inc and Roche Holding AG, analysts said.</p><P>It cements the role of local</p> <p><a href="http://www.globalpost.com/dispatch/news/asianet/130403/novartis-loses-landmark-india-cancer-drug-patent-case" target="_blank">read more</a></p> BSE Sensex Business Health Hospitality Labor Law Novartis Patent law Politics Social Issues Technology Asianet Wed, 03 Apr 2013 17:46:20 +0000 Asianet 5800843 at http://www.globalpost.com India defends rejection of Novartis patent bid http://www.globalpost.com/dispatch/news/afp/130408/india-defends-rejection-novartis-patent-bid <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>An Indian court was fully justified to reject a patent bid by Swiss drug giant Novartis last week, India's trade and industry minister insisted in Geneva on Monday, defending the country's generic drug business.</p> <p>"The reasons for the denial .. are absolutely justified under the law," Anand Sharma told reporters following a ceremony marking his country's accession to the Madrid Protocol, an international trademark system.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130408/india-defends-rejection-novartis-patent-bid" target="_blank">read more</a></p> Business Hospitality Law Novartis Patent law Pharmaceutical sciences Politics Social Issues AFP Mon, 08 Apr 2013 15:32:14 +0000 5805662 at http://www.globalpost.com U.S. sues Novartis, alleging kickbacks to pharmacies http://www.globalpost.com/dispatch/news/thomson-reuters/130423/us-sues-novartis-over-alleged-fraudulent-kickbacks <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>By Bernard Vaughan and Jonathan Stempel</p> <p>(Reuters) - The U.S. government filed a civil fraud lawsuit against Novartis AG &lt;NOVN.VX&gt; on Tuesday, accusing a unit of the Swiss drug maker of causing the Medicare and Medicaid programs to pay tens of millions of dollars in reimbursements based on fraudulent, kickback-tainted claims.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130423/us-sues-novartis-over-alleged-fraudulent-kickbacks" target="_blank">read more</a></p> Federal assistance in the United States Health Healthcare reform in the United States Labor Novartis Pharmaceutical industry Pharmaceutical sciences Presidency of Lyndon B. Johnson Social Issues Thomson Reuters Tue, 23 Apr 2013 21:15:34 +0000 5823594 at http://www.globalpost.com Pharma giant Novartis working on H7N9 vaccine http://www.globalpost.com/dispatch/news/afp/130425/pharma-giant-novartis-working-h7n9-vaccine <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Swiss pharmaceuticals giant Novartis is researching a vaccine for the H7N9 strain of bird flu, its chief executive said Thursday, amid fears that the disease could mutate into a form that spreads among people.</p> <p>In an interview with the Swiss daily Tagesanzeiger, Joe Jimenez said that Novartis had already analysed the virus' genetic codes, which have been published by Chinese authorities.</p> <p>Jimenez said that Novartis "would today be in a position to develop a vaccine for initial clinical trials within six to eight weeks".</p> <p>"The need is theoretical for now," he added.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130425/pharma-giant-novartis-working-h7n9-vaccine" target="_blank">read more</a></p> Disaster Health Medicine Novartis AFP Thu, 25 Apr 2013 13:31:31 +0000 5825055 at http://www.globalpost.com U.S. sues Novartis over kickbacks, second case this week http://www.globalpost.com/dispatch/news/thomson-reuters/130426/us-files-second-lawsuit-accusing-novartis-kickbacks <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>By Jonathan Stempel</p> <p>NEW YORK (Reuters) - The U.S. government on Friday announced its second civil fraud lawsuit against Novartis AG &lt;NOVN.VX&gt; in four days, accusing a unit of the Swiss drugmaker of paying multimillion-dollar kickbacks to doctors in exchange for prescribing its drugs.</p> <p>Authorities said the Basel-based company for a decade lavished healthy speaking fees and "opulent" meals, including a nearly $10,000 (6,459 pounds) dinner for three at the Japanese restaurant, Nobu, to induce doctors to prescribe its drugs.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130426/us-files-second-lawsuit-accusing-novartis-kickbacks" target="_blank">read more</a></p> Combination drugs Health Labor Law Novartis Pharmaceutical sciences Pharmacology Social Issues Thomson Reuters Fri, 26 Apr 2013 19:15:04 +0000 5826315 at http://www.globalpost.com